Lyell Immunopharma (LYEL) Shares Outstanding (2020 - 2026)

Lyell Immunopharma has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $23.3 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 58.01% year-over-year to $23.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.3 million (up 58.01% YoY) and the FY2025 annual result came in at $17.1 million, up 15.93% from the prior year.
• Shares Outstanding (Entity) improved to $23.3 million in Q1 2026 per LYEL's latest filing, from $17.1 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $23.3 million in Q1 2026 and troughed at $12.3 million in Q1 2022.
• A 5-year average of $14.3 million and a median of $12.7 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) surged 578341.01% in 2022, then advanced 1.05% in 2023.
• Over 5 years, Shares Outstanding (Entity) stood at $12.5 million in 2022, then rose by 1.76% to $12.7 million in 2023, then increased by 16.11% to $14.7 million in 2024, then increased by 15.93% to $17.1 million in 2025, then surged by 36.48% to $23.3 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $23.3 million, $17.1 million, and $19.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.